Volume : 12, Issue : 08, August- 2025
Title:
DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF DRONEDARONE IN PURE FORM AND MARKETED PHARMACEUTICAL DOSAGE FORMS
Authors :
B.Raj Kumar*, Akhila.G, Navya.K, Akshitha.K, Vaishnavi.K, Jagadeesh.P
Abstract :
In the present work an attempt is being made to provide for stable drug delivery system with or having improved therapeutic index for Irinotecan in form of lyophilized liposomes. Liposomes were prepared using the thin-film hydration method and optimized for various formulation parameters. The developed liposomal formulations were evaluated for particle size, zeta potential, drug entrapment efficiency, in vitro drug release and stability. Irinotecan containing liposomes with an encapsulation efficiency of 92.67 % were prepared, and the in vitro release of Irinotecan from the liposomes. In conclusion, the formulation was optimized, the prepared liposomes had a high Irinotecan encapsulation rate and good reproducibility, and there in vitro release had a certain delayed-release effect. The optimized formulation exhibited nanoscale particle size (236 nm), high entrapment efficiency (>80%), and a sustained drug release profile over 8 hours. The liposomal encapsulation of Irinotecan showed potential for improved pharmacokinetics and site-specific targeting, thereby minimizing systemic toxicity. In conclusion, the liposomal delivery system developed in this study demonstrates a promising approach to enhance the therapeutic efficacy and safety of Irinotecan.
Keywords: Irinotecan, Cholesterol, phosphatidyl choline, FTIR studies, thin film hydration technique, In vitro drug release studies.
Cite This Article:
Please cite this article in press Alvia Anjum et al., Formulation And Evaluation Of Irinotecan Liposomal For Targeted Drug Delivery., Indo Am. J. P. Sci, 2025; 12(08). .
Number of Downloads : 10
References:
1. Benita S. Microencapsulation Method and Industrial Application, Drug and Pharmaceutical sciences. Vol.73 2002. p. 213.
2. Fuji G. Vesicles, Realization of the Drug Delivery Concept. Vol.62 1996. New York p. 491-495.
3. Bangham AD, Standish MM. Diffusion of univalent ions across the lamella of swollen Phospholipids. J. Mol. Biol. 1965; 13: 238-252.
4. Vyas SP, Khar RK. Targeted and controlled Drug Delivery, Novel Carrier system, CBS Publishers and distributors. 2002. p. 249.
5. Gregoriadis G. Liposome technology, Liposome preparation and related techniques, 3rd edition, vol. l 2007. p. 21.
6. Singh S, Gulati M. Advances in liposomal therapeutics, Targeting of drugs to lipid bilayer in liposomes: an approach for the success of liposomes as delivery systems. CBS Publishers and distributors. New Delhi. 2001. p. 4-34.
7. Scherphof G, Morselt H, Regts J. The involvement of the lipid phase transition in the plasma-induced dissolution of multilamellar phosphatidylcholine vesicles. Biochem. Biophys. Acta.1979;556:196–207.
8. Jain NK. Controlled and novel drug Delivery, CBS Publishers and distributors.2002. p. 305,326,330.
9. Bangham AD. Techniques in life Science, lipid membrane biochemistry. Elsevier scientific publications. Ireland. 1982 p.1-25.
10. Drummond DC, Meyer O, Hong K. Pharmacokinetic study of liposome encapsulated drug. Pharmacological reviews 1999; 51(4): 691-743.11.
11. Lasic DD. Stealth liposomes, Microencapsulation Method and Industrial Applications. Vol. 73 1996 p. 297-311.
12. Crommelin DJ, Schreier H. Liposomes, Colloidal Drug Delivery Systems. 1996 p. 73-157.
13. Liu R, Cannon JB, Li Y. Liposomes in Solubilization. Water Insoluble Drug Formulation CRC Press, New York. 2000; 355-358.
14. Patel HM, Ryman BR. Systemic and Oral administration of liposomes. Physical Structure to therapeutic applications 1981; 409-439.